A142760 Share Price Performance
₩0
-1300.00 (-100.00%)
Price ₩0
Share Pricen/a
Is MOA Life Plus (KOSDAQ:142760) Using Debt In A Risky Way?
Jan 22
MOA Life Plus Co. Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A142760 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
MOA Life Plus Co. Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -292.32
- 24.00%
- -121.73%
- 29.8%
About A142760
- Founded
- 1999
- Employees
- 41
- CEO
- WebsiteView website
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.
